Danaher Corp. said it expects adjusted full-year core revenue growth including Cytiva to be about 20%, up from its prior guidance of a growth in the high-teens percentage.
For the third quarter, the Washington, D.C.-based science and technology conglomerat Thursday said it expects adjusted core-revenue growth to be in the mid- to high-teens percentage range.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.